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an inadequate response to methotrexate. The aim of this work is to estimate 
the budget impact of the inclusion of tofacitinib in the public list of reimburse-
ment in Colombia. METHODS: A model was built with a time horizon of three 
years. The comparators were:abatacept, adalimumab, certolizumab, etanercept, 
infliximab, golimumab, rituximab, tocilizumab, and tofacitinib. The perspective 
was of the Colombian health system including only direct costs: drug costs and 
administration costs. All currency units were in USD $ (1 USD$ = COP 1,971). A 
5% discount rate was used. The number of expected cases was calculated from 
the single national register of members of the Colombian health system (BDUA). 
Additionally a prevalence of 0.52% was used and we assumed that 30% of patients 
were refractory to initial treatment with non-biologic DMARDs. The costs of drugs 
were used current price regulation and the official database of purchase and sale 
of drugs (SISMED). The market share was estimated based on SISMED and the pro-
jected demand validated by expert physician. RESULTS: As the use of tofacitinib 
is increased from 0.9% (current scenario) to 15.3% (projected for three years) total 
spending is reduced in USD $ 80,345,510 equivalent to 5% of total expenditure of 
this pathology in Colombia. CONCLUSIONS: The use of tofacitinib in patients who 
have an inadequate response to methotrexate, decreases total costs of care for the 
health system in Colombia.
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OBJECTIVES: To conduct budget impact analysis of abobotulinumtoxinA, onabotuli-
numtoxinA, incobotulinumtoxinA in patients with post-stroke spasticity in Russia 
for 1-year period. Physical therapy was used in all therapy schemes. METHODS: A 
budget impact model was developed in Excel 2013 to simulate the costs of abobo-
tulinumtoxinA, onabotulinumtoxinA, incobotulinumtoxinA. The total number of 
patients in Russian Federation is 287,334. According to the performed modeling 
using up-to-date epidemiological data only 212,126 people survive by the 1st year 
of therapy. The following costs were taken into account:, the costs of pharmaco-
therapy, costs of inpatient and outpatient care in the Russian Federation, costs of 
adverse events, disability pensions, GDP loss due to post-stroke spasticity (PPS). 
Costs of pharmacotherapy were taken from the essential drug list and the data-
base of drugs prices. Standard of treatment of stroke consequences developed by 
Ministry of Health of the Russian Federation was used for calculation of medi-
cal care costs. Costs of adverse events were calculated basing on Russian clini-
cal guidelines and database of drugs prices. Disability pensions were taken from 
Russian Pension Fund database. GDP loss was based on the GDP information from 
World Bank. For reference, accepted exchange rate was 1 US$ = 60,29 RUB. RESULTS: 
AbobotulinumtoxinA treatment in whole population of PPS patients in Russia will 
result in US$ 185,07 million economy for 1 year compared with onabotulinumtoxinA, 
US$ 183,13 million economy compared with IncobotulinumtoxinA and will result in 
US$ 756 economy for 1 year compared with onabotulinumtoxinA, US$ 737 economy 
compared with incobotulinumtoxinA per one patient. This cost reduction is mainly 
attributed to decrease of GDP loss, disability pensions due to the better efficacy of 
this BTA drug. CONCLUSIONS: Inclusion of abobotulinumtoxinA therapy is the most 
cost saving treatment option in the management of post-stroke spasticity in Russia 
compared with other BTA medications.
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OBJECTIVES: A number of therapeutic classes are available to treat psoriatic 
arthritis (PsA), including biologic drugs. Although the wholesale acquisition cost 
of biologic drugs has increased in recent years, there is little published evidence 
documenting cost trends from the US perspective. The objective of this study was 
to assess cost trends for patients using biologic therapy for PsA from the US per-
spective. METHODS: Continuously enrolled adult patients with ≥ 2 outpatient 
diagnoses of PsA were selected from the MarketScan databases if their first bio-
logic prescription date (index date) occurred between July 1, 2008, and July 31, 2013. 
Patients were included in the study if (1) full access was available to all medical 
and pharmacy claims for ≥ 6 months before and ≥ 12 months after their index date, 
and (2) they were biologic-naïve before index. Healthcare costs were assessed from 
the payer perspective and based on annual reimbursed amounts. Results were 
stratified by all-cause vs. PsA-related costs and within these 2 categories further 
subdivided into medical inpatient, medical outpatient, emergency room, and phar-
macy costs. RESULTS: In total, 25,565 patients met the inclusion criteria. All-cause 
healthcare costs in the 6 annual cohorts increased by 53.1% between 2008 and 
2013, with an average annual increase of 10.6% (or $2,867). PsA-related annual costs 
were estimated to increase by 63.6%, with an average annual increase of 12.7% (or 
$2,335). Although cost increases in all categories of interest were observed over 
time, the major driver of the observed trends was the PsA-related pharmacy costs, 
predominantly the cost of biologic therapy, with an estimated increase of 65.6% and 
an average annual increase of 13.1% (or $2,220). CONCLUSIONS: For US managed 
care payers, total healthcare costs among patients initiated on biologic therapy for 
PsA has increased by 53.1%, which is mostly driven by the 65.6% change in PsA-
related pharmacy costs.
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tively. QALYs were significantly lower for the most sedentary (Q1) group relative 
to the two least sedentary groups (Q3 and Q4) adjusted for age, gender, and BMI. 
Furthermore, for average overweight women age 65, every additional hour spent 
in sedentary behavior was associated with greater decreases in median QALYs for 
those who were more sedentary than those who were less sedentary (Q1: -0.049, 
95%CI: -0.074, -0.025; Q2: -0.058, 95% CI: -0.135,0.019; Q3: -0.031, 95% CI: -0.092,0.030; 
Q4: 0.01, 95% CI: -0.006,0.032). CONCLUSIONS: Persons in the most sedentary group 
suffered the greatest QALY losses. Study results support interventions targeting the 
most sedentary persons in reducing this behavior.
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OBJECTIVES: To assess the validity of a previously published, updated denosumab 
budget impact model (BIM), evaluating the budgetary impact to a hypothetical US 
health plan of increased utilization of denosumab in postmenopausal women with 
osteoporosis at high risk of fracture. METHODS: The BIM was evaluated using face 
validity, internal validity and cross validity tests. Face validity of the model was 
assessed by comparing the underlying Markov model with prior published osteopo-
rosis cost-effectiveness studies and osteoporosis reference model. Internal validity 
was assessed using: 1) extreme value analyses on input parameters; and 2) two-way 
sensitivity analyses by simultaneously varying the market share, price of deno-
sumab, and direct medical costs of fractures. Cross validity tests were conducted on 
the following input parameters: population parameters, treatment persistence rate 
and direct medical costs of fractures. RESULTS: In a base case analysis, increasing 
utilization of denosumab up to 19.6% of eligible patients in year 3 compared with a 
constant 16% in years 1 through 3, resulted in a net per-member-per-month (PMPM) 
of < $0.0025 in each year. The use of a well-validated osteoporosis Markov model 
with health states aligned with osteoporosis reference model suggests face validity 
for the BIM. The results of the BIM model varied in expected directions in internal 
validity tests: extreme value analysis showed the model was sensitive to the pro-
portion of population currently or newly treated with osteoporosis medication. In 
the two-way sensitivity analyses, the PMPM increased with increases in price and 
market share of denosumab. The input parameters used in the model fell within the 
ranges published in literature, thus providing cross validity. CONCLUSIONS: The 
current study showed that the denosumab BIM is well validated and can serve as a 
useful tool to assess the potential impact to a US health plan’s budget of increased 
denosumab utilization in postmenopausal osteoporosis.
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OBJECTIVES: Upper limb spasticity (ULS) secondary to stroke has a considerable 
patient and caregiver burden, particularly with regards to pain, activities of daily 
living and mobility. Botulinum neurotoxin-A (BoNT-A) injections are effective in 
treating ULS. We aimed to calculate annual cost per-patient basis and the expected 
overall annual budget impact in Hong Kong using static and dynamic market share 
scenarios. METHODS: A budget impact model for BoNT-A use, adopting a Hong 
Kong healthcare system perspective, was developed. Two market-share scenarios 
were modelled over 5 years. While the static scenario assumed current market 
shares (abobotulinumtoxinA, 24%; onabotulinumtoxinA, 76%) to remain constant 
over time, the dynamic scenario assumed market share of abobotulinumtoxinA 
to rise up to 65% across 5 years. Epidemiologic data inputs were sourced from the 
most recently published literature, unit costs for BoNT-As, healthcare resources use 
from physicians working in Hong Kong, and market share assumptions from IMS 
Health (Market Sizing). Equivalence of the 2 BoNTAs in terms of efficacy and safety 
is assumed but the units of abobotulinumtoxinA are specific to the preparation 
and are not interchangeable with other preparations of botulinum toxin. RESULTS: 
Annual cost per ULS patient were 59 907 HKD, and 76 888 HKD respectively, with 
prescribing patterns following SmPC recommendations for abobotulinumtoxinA 
and onabotulinumtoxinA. The annual budget impact was decreased by between 28 
731 553 HKD in year 2 and 111 142 610 HKD in year 5 by shifting the market share 
to abobotulinumtoxinA. Sensitivity analyses showed that time to re-injection, and 
dose per injection for both toxins were the most influential parameters on budget 
impact, impacting both drug acquisition costs and physician visits. CONCLUSIONS: 
Increased use of abobotulinumtoxinA relative to onabotulinumtoxinA could poten-
tially reduce the total cost of treating ULS patients in Hong Kong.
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OBJECTIVES: Tofacitinib is an oral small molecule Janus kinase inhibitor for the 
treatment of moderate to severe rheumatoid arthritis (RA) in adults who have 
